Evidence map›Paper›PMID 37122898›Full record

ArticleBioactive materials2023

A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy.

Bin Xu, Fanjun Zeng, Jialong Deng, Lintong Yao, Shengbo Liu, Hengliang Hou, Yucheng Huang, Hongyuan Zhu, Shaowei Wu, Qiaxuan Li and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Biomimetic materials for medical applications.Chinese medical journal · 2026
    Review
  3. Article
  4. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Nanotechnology boosts the efficiency of tumor diagnosis and therapy.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Bin XuDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Fanjun ZengDepartment of General Practice, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Jialong DengSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, PR China.
Lintong YaoDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Shengbo LiuThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, PR China.
Hengliang HouSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, PR China.
Yucheng HuangSchool of Medicine, South China University of Technology, Guangzhou, 510006, PR China.
Hongyuan ZhuDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Shaowei WuThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, PR China.
Qiaxuan LiDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Weijie ZhanThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, PR China.
Hongrui QiuGuangzhou University of Chinese Medicine, Guangzhou, 510006, PR China.
Huili WangGuangzhou University of Chinese Medicine, Guangzhou, 510006, PR China.
Yundong LiSouth China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of South China Sea Fishery Resources Exploitation and Utilization, Ministry of Agriculture and Rural Affairs, Guangzhou, 510300, China.
Xianzhu YangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, PR China.
Ziyang CaoGuangzhou First People's Hospital, South China University of Technology, Guangzhou, 510006, PR China.
Yu ZhangDepartment of Orthopedics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China.
Haiyu ZhouDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Guangdong Academy of Medical Sciences · CNGuangzhou University of Chinese Medicine · CNShantou University · CNGuangzhou First People's Hospital · CNMinistry of Agriculture and Rural Affairs · CNSouth China University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The abnormal activation of epidermal growth factor receptor (EGFR) drives the development of non-small cell lung cancer (NSCLC). The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR mutation. However, free osimertinib administration exhibits an inadequate response in vivo, with only ∼3% patients demonstrating a complete clinical response. Consequently, we designed a biomimetic nanoparticle (CMNP

Indexed as

Biomimetic nanoparticlesClinical efficacyEGFR mutationIntracellular drug deliveryMembrane targetingNon-small cell lung cancerTyrosine kinase inhibitor

Identifiers

PMID37122898
PMCPMC10140750
OpenAlexW4366382790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.